Novo Integrated Sciences's Days Sales Outstanding for the
three
months ended in May. 2024 was 86.5.
Novo Integrated Sciences's Days Inventory for the
three
months ended in May. 2024 was 41.66.
Novo Integrated Sciences's Days Payable for the
three
months ended in May. 2024 was 122.79.
Therefore, Novo Integrated Sciences's Cash Conversion Cycle (CCC) for the
three
months ended in May. 2024 was 5.37.
Novo Integrated Sciences (OTCPK:NVOS) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Novo Integrated Sciences Cash Conversion Cycle Related Terms
Novo Integrated Sciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Novo Integrated Sciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences Cash Conversion Cycle Chart
NVOS vs BACK, NHLG, FCHS: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Integrated Sciences Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Cash Conversion Cycle falls into.
Novo Integrated Sciences Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Novo Integrated Sciences's Cash Conversion Cycle for the fiscal year that ended in Aug. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences (NVOS) has a Cash Conversion Cycle of 5.37 as of May. 2024. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Novo Integrated Sciences and its competitors.
Is Novo Integrated Sciences' Cash Conversion Cycle too high?
Novo Integrated Sciences' current Cash Conversion Cycle is 5.37. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.32. Novo Integrated Sciences' value of 5.37 is 70.7% below this industry median. Overall, Novo Integrated Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novo Integrated Sciences' Cash Conversion Cycle compare to BACK and NHLG?
Novo Integrated Sciences' Cash Conversion Cycle of 5.37 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.32. Novo Integrated Sciences' value of 5.37 is 70.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.32, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Integrated Sciences's current Cash Conversion Cycle of 5.37 is 70.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Novo Integrated Sciences and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Integrated Sciences's current Cash Conversion Cycle is 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Integrated Sciences stock overvalued right now?
Novo Integrated Sciences (NVOS) has a current Cash Conversion Cycle of 5.37. The current Cash Conversion Cycle is 5.37 and 70.7% below the Healthcare Providers & Services industry median of 18.32. Novo Integrated Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Novo Integrated Sciences (NVOS), the current Cash Conversion Cycle is 5.37 as of May. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
12GF Score
Get the complete analysis for NVOS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVOS has been successfully added to your 
